Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Marsden

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Cell|August 30, 2014
Neutralizing the HIV reservoirMatthew D Marsden, Jerome A Zack
Annual Review of Virology|July 27, 2017
Humanized Mouse Models for Human Immunodeficiency Virus InfectionMatthew D Marsden, Jerome A Zack
Plos One|April 13, 2011
Activation of latent HIV using drug-loaded nanoparticlesMichael Kovochich, Matthew D Marsden, Jerome A Zack
Antiviral Therapy|July 24, 2012
Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimensMatthew D Marsden, Paul A Krogstad, Jerome A Zack
Viruses|July 27, 2024
HIV Persistence, Latency, and Cure Approaches: Where Are We Now?Tessa C Chou, Nishad S Maggirwar, Matthew D Marsden
Frontiers in Immunology|June 13, 2022
Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure ApproachesJose A Moran, Shireen R Turner, Matthew D Marsden
Virology|July 23, 2011
HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genesMatthew D Marsden, Bryan P Burke, Jerome A Zack
AIDS Research and Human Retroviruses|November 13, 2008
Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophagesMatthew D Marsden, Jie Xu, Dean Hamer, et al.
Antimicrobial Agents and Chemotherapy|June 2, 2011
Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophagesMatthew D Marsden, Patricia Avancena, Christina M R Kitchen, et al.
Journal of Virology|May 4, 2007
Primary cell model for activation-inducible human immunodeficiency virusBryan Burke, Helen J Brown, Matthew D Marsden, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Cell|August 30, 2014
Neutralizing the HIV reservoirMatthew D Marsden, Jerome A Zack
Annual Review of Virology|July 27, 2017
Humanized Mouse Models for Human Immunodeficiency Virus InfectionMatthew D Marsden, Jerome A Zack
Plos One|April 13, 2011
Activation of latent HIV using drug-loaded nanoparticlesMichael Kovochich, Matthew D Marsden, Jerome A Zack
Antiviral Therapy|July 24, 2012
Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimensMatthew D Marsden, Paul A Krogstad, Jerome A Zack
Viruses|July 27, 2024
HIV Persistence, Latency, and Cure Approaches: Where Are We Now?Tessa C Chou, Nishad S Maggirwar, Matthew D Marsden
Frontiers in Immunology|June 13, 2022
Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure ApproachesJose A Moran, Shireen R Turner, Matthew D Marsden
Virology|July 23, 2011
HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genesMatthew D Marsden, Bryan P Burke, Jerome A Zack
AIDS Research and Human Retroviruses|November 13, 2008
Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophagesMatthew D Marsden, Jie Xu, Dean Hamer, et al.
Antimicrobial Agents and Chemotherapy|June 2, 2011
Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophagesMatthew D Marsden, Patricia Avancena, Christina M R Kitchen, et al.
Journal of Virology|May 4, 2007
Primary cell model for activation-inducible human immunodeficiency virusBryan Burke, Helen J Brown, Matthew D Marsden, et al.
Pageof 5